
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
A drug used to treat skin infections including athlete's foot, could help to slow the progression of Alzheimer's disease, scientists say.






